SLU-PP-332
Also known as: SLU PP 332, SLU-PP332, 332
4 notable studies · 4 references
TLDR
SLU-PP-332 is an experimental small-molecule ERRα/β/γ agonist that activates portions of an aerobic-exercise-like metabolic program and improves endurance, fat metabolism, insulin sensitivity, and cardiac metabolism in mouse models, but controlled human administration evidence is currently lacking.
Research Supports
- Studied as an exercise-mimetic activator of ERRα/β/γ nuclear receptors
- Investigated for effects on mitochondrial metabolism and fatty-acid oxidation
- Examined for effects on exercise endurance and skeletal-muscle fiber type in mice
- Studied in mouse models of obesity, insulin sensitivity, and cardiac metabolism/heart failure
Observations Reported in Research
- Increased oxidative skeletal-muscle fibers and running endurance in an ERRα-dependent manner (Billon et al., 2023)
- Increased energy expenditure and fatty-acid oxidation while reducing fat accumulation and improving insulin sensitivity in obese mice (Billon et al., 2024)
- Improved ejection fraction, fibrosis, and survival in a mouse pressure-overload heart-failure model (2023)
- Identified 22 Phase I/II metabolites using human liver S9 fractions, informing possible doping-control detection (2026)
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic small-molecule estrogen-related receptor pan-agonist; ERRα/β/γ agonist; experimental exercise-mimetic compound
SLU-PP-332 is an experimental small molecule, not a peptide. It activates the three estrogen-related receptors (ERRα, ERRβ, and ERRγ), with particularly important activity involving ERRα. Despite their name, estrogen-related receptors are not the same thing as estrogen receptors. ERRs are nuclear receptors involved heavily in mitochondrial metabolism, fatty-acid oxidation, oxidative phosphorylation, skeletal-muscle adaptation, energy expenditure, and cardiac metabolism. SLU-PP-332 became famous after researchers showed that it could activate an aerobic-exercise-like transcriptional program and improve running endurance in mice. Subsequent mouse studies reported increased energy expenditure, increased fatty-acid oxidation, reduced fat accumulation, improved insulin sensitivity, improved exercise endurance, and cardiac benefits in experimental heart failure. Hence the nickname “exercise mimetic.” That phrase is very easy to abuse. SLU-PP-332 reproduces certain molecular and metabolic adaptations associated with aerobic exercise in experimental models. It does not reproduce everything exercise does, and there is currently no established evidence that taking SLU-PP-332 provides the health benefits of exercising in humans.
What Is SLU-PP-332?
ERRs are orphan nuclear receptors. That means they're transcription factors related structurally to steroid-hormone receptors, but they do not use estrogen as their physiological ligand. The receptors regulate genes involved in energy metabolism. Researchers had long suspected that activating ERRα pharmacologically might reproduce some of the metabolic adaptations caused by endurance exercise. But developing a useful ERRα agonist proved difficult. SLU-PP-332 was designed as a synthetic agonist capable of activating ERRα, ERRβ, and ERRγ and functioning sufficiently well in vivo to test that hypothesis.
What Are Researchers Studying?
Exercise mimetics
This is the defining research area. Exercise activates complex transcriptional programs in skeletal muscle. SLU-PP-332 induced expression of genes associated with an acute aerobic-exercise response, including an ERRα-dependent program. Treated mice developed more oxidative type IIa muscle fibers and demonstrated increased exercise endurance. That earned SLU-PP-332 the “exercise mimetic” label. But: Exercise mimetic ≠ exercise replacement. Physical exercise affects muscle, bone, tendons, brain, vasculature, heart, immune function, balance, coordination, mechanical loading, and cardiorespiratory fitness. A compound activating part of an exercise-associated metabolic program does not reproduce that entire physiology.
Mitochondrial metabolism
ERRs regulate numerous genes involved in mitochondrial function, oxidative phosphorylation, fatty-acid metabolism, and Krebs-cycle activity. In cultured skeletal-muscle cells, SLU-PP-332 increased mitochondrial respiration. This provides a mechanistic foundation for its endurance and metabolic effects.
Exercise endurance
In mice, SLU-PP-332 increased running endurance. Genetic experiments showed that the endurance effect depended substantially on ERRα, strengthening the causal link between the target and the observed phenotype. This is much stronger mechanistic evidence than simply observing that treated animals happened to run farther. Still: Mouse endurance ≠ human athletic-performance evidence.
Obesity and fat metabolism
Researchers subsequently tested SLU-PP-332 in obese mice. Treatment increased energy expenditure and fatty-acid oxidation, while reducing fat accumulation and obesity, and improving insulin sensitivity. Importantly, this represents pharmacological alteration of metabolism in mice, not evidence for human fat loss.
Insulin sensitivity
SLU-PP-332 improved insulin sensitivity in mouse models of metabolic syndrome. Because exercise itself improves insulin sensitivity, this finding supports the broader exercise-mimetic hypothesis. Whether a similar effect occurs safely and meaningfully in humans remains unknown.
Heart failure and cardiac metabolism
The heart depends heavily on mitochondrial energy metabolism. ERRα and ERRγ are important regulators of cardiac metabolic programs. In a mouse pressure-overload heart-failure model, SLU-PP-332 and a related ERR agonist improved ejection fraction, fibrosis, and survival, while enhancing cardiac fatty-acid metabolism and mitochondrial function. This makes ERR activation an interesting potential therapeutic strategy. It absolutely does not make SLU-PP-332 an established heart-failure treatment.
Aging and skeletal muscle
A 2025 pilot study examined muscle tissue and cells from physically active and inactive older women. The researchers treated human-derived myoblasts in culture with SLU-PP-332 and observed changes in oxidative-stress, mitochondrial, survival, and differentiation-related pathways. This is sometimes easy to misread as a human trial. It wasn't. The people did not receive SLU-PP-332. Their cells were treated experimentally outside the body.
How Does It Work?
SLU-PP-332 activates ERRα / ERRβ / ERRγ. ERRs bind regulatory regions of DNA. Transcription of metabolic genes changes. Increased programs involving mitochondrial function, fatty-acid oxidation, oxidative metabolism, and skeletal-muscle energetics. Experimental phenotypes resembling portions of aerobic exercise adaptation. ERRα appears especially important. Genetic loss of ERRα substantially altered SLU-PP-332's exercise-related effects.
What Does the Research Show?
Human research
There are currently no established controlled human administration trials demonstrating SLU-PP-332 efficacy or safety. Human-derived cells have been studied. Human liver preparations have also been used experimentally to characterize metabolism. Those are not human clinical trials. Evidence hierarchy: cellular evidence yes; animal efficacy yes; human-derived tissue/cells yes; human therapeutic administration not established.
Animal research
Mouse studies demonstrate increased endurance, more oxidative muscle fibers, exercise-like gene expression, increased fatty-acid oxidation, increased energy expenditure, reduced adiposity, improved insulin sensitivity, and improved cardiac metabolism in disease models. The findings are scientifically exciting. They're still mouse findings.
In-vitro research
Cellular studies have demonstrated ERR activation, increased mitochondrial respiration, altered metabolic gene expression, effects on muscle-cell differentiation, and metabolic transformation in human liver preparations. Recent 2026 work has also mapped the structure-activity relationships of the SLU-PP-332 chemical scaffold, helping researchers develop newer ERR agonists with improved properties.
Notable Studies
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
animalResearchers developed SLU-PP-332 as a pan-ERR agonist with particularly strong ERRα activity. The compound increased mitochondrial function in muscle cells, increased oxidative skeletal-muscle fibers in mice, induced an aerobic-exercise-like transcriptional program, and enhanced running endurance. Genetic experiments demonstrated that ERRα was critical to the endurance response.
Limitations: Preclinical study. Improved mouse running performance does not establish human exercise capacity, safety, or health outcomes.
View publication →A Synthetic ERR Agonist Alleviates Metabolic Syndrome
animalResearchers tested SLU-PP-332 in diet-induced obese and genetically obese mice. Treatment increased whole-body energy expenditure and fatty-acid oxidation, reduced fat accumulation and obesity, and improved insulin sensitivity.
Limitations: Mouse models only. The study does not establish human weight-loss efficacy, safe exposure, or long-term metabolic outcomes.
View publication →Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
animalSLU-PP-332 and SLU-PP-915 were evaluated in pressure-overload heart failure. ERR activation improved ejection fraction, reduced fibrosis, improved survival, and restored aspects of cardiac fatty-acid and mitochondrial metabolism.
Limitations: Experimental mouse heart failure does not establish clinical benefit or safety in human heart failure.
View publication →Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes
in-vitroResearchers incubated SLU-PP-332 with pooled human liver S9 fractions and identified 22 Phase I/II metabolic products, several of which may be useful for future doping-control detection.
Limitations: This was laboratory metabolism research, not administration to humans. It establishes possible metabolic pathways rather than human pharmacokinetics, efficacy, or safety.
View publication →What We Still Don't Know
Whether SLU-PP-332 is safe in humans; human pharmacokinetics; human bioavailability; human dose-response relationships; whether it improves human exercise capacity; whether it causes human fat loss; whether it improves human insulin sensitivity; long-term consequences of pan-ERR activation; cardiovascular safety; liver safety; reproductive effects; cancer-related consequences of chronic metabolic transcription changes; whether human benefits would persist with chronic exposure; whether the compound interacts adversely with actual exercise; whether research-market material corresponds chemically to published SLU-PP-332. SLU-PP-332 lacks useful oral bioavailability. Researchers subsequently developed SLU-PP-915, a chemically distinct, orally bioavailable pan-ERR agonist that retained exercise-mimetic activity in mice. That makes claims around orally consumed research-market “SLU-PP-332” particularly worth scrutinizing.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the SLU-PP-332 research with you.
Get the Aminodex SLU-PP-332 Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Billon C, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. 2023.
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome. 2024.
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. 2023.
- Avliyakulov NK, Sobolevsky T, Ahrens E. Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. 2026.
Supplier Listings
Disclosure: The owner of Aminodex operates the supplier(s) marked below. These listings are promotion for businesses we own, not independent recommendations. Read our disclosures.